Login to Your Account



Earnings Roundup


Monday, August 8, 2011
Allos Therapeutics Inc., of Westminster, Colo., reported that second quarter net sales of peripheral T-cell lymphoma drug Folotyn (pralatrexate) increased 39 percent to $11 million compared to $7.9 million for the same quarter in 2010.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription